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1. Executive Summary 
Research in transdermal drug delivery systems has gained much attention in the past 
thirty years. One of the biggest challenges in developing an effective system however, is getting 
past the tightly-structured outermost layer of the skin called the stratum corneum. While many 
different techniques to safely bypass the stratum corneum have been employed, one promising 
method of transdermal drug delivery is the use of drug-loaded microcapsules. Encapsulating the 
drug, as opposed to a non-encapsulated topical application, allows the drug to diffuse into hair 
follicles where drug release can occur in the deeper layers of the skin. 
COMSOL was used to model the diffusion of drug through a hair follicle and into the 
skin layers, via microcapsules of inner radius 300nm and outer radius 350nm. The diffusion of 
microcapsules through the hair follicle, drug through the microcapsule shell, and drug through 
the skin layers was modeled using three transient diffusion equations that were solved 
simultaneously. The drug in microcapsules was modeled as emerging from a source, similar to a 
patch, above the hair follicle. 
The COMSOL model was verified by comparing the time for the microcapsules to 
penetrate into the follicle, the time for the drug to diffuse out of the microcapsules, and the drug 
concentration in the dermis to literature values. It took 60-70 minutes for the microcapsules to be 
evenly dispersed throughout the follicle, which is supported by literature values.
1
 The 
microcapsule released 75% of its encapsulated drug after 1.25 hours, which is comparable to a 
literature value of 70% release in 2 hours.
1 
Additionally, the same source showed that drug 
release by the microcapsule was complete after 4 hours; almost all of the drug had left the 
microcapsule in 4 hours in our model. The drug concentration in the dermis in our model after 4 
hours (0.0005 ug/mL) was lower than literature sources. However, our design only had drug-
containing microcapsules applied directly above the hair follicle, when in reality, much more 
drug would be applied to the skin surface.
2
 We showed that a slight variation of our design, using 
a thin layer of drug over the entire skin surface, greatly improves the value of drug concentration 
in the dermis.  A sensitivity analysis was conducted to determine the significance of parameters 
on our model. 
The solution from our design led to a slightly high release rate of the drug and a low final 
drug concentration in the skin, relative to literature values. This indicated that our model would 
best reflect the behavior of a potent drug requiring a fast release rate and a low dosage in skin. In 
order to obtain a more accurate solution, the simplifications in our design could be adjusted and 
the realistic complexities of actual skin could be added. While we only studied diffusion through 
one hair follicle, studying several hair follicles in a representative region of the skin could lead to 
changes in the final drug concentration achieved in the skin. Despite the many simplifications of 
our model, we were able to show that this microcapsule transdermal system is an effective 
method for bypassing the highly impermeable outer skin layer. 
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2. Introduction 
2.1 Background 
Drug delivery through the skin has been a rapidly growing area of research in the past 
thirty years. Compared to the conventional methods for drug delivery such as oral intake or 
injections, transdermal drug delivery has proven to have several advantages. Drugs administered 
transdermally avoid both degradation in the gastro-intestinal tract and the first-pass effects of the 
liver
3,4,5,6
 , which are typical problems associated with oral delivery.  Injections are painful, 
inconvenient, and invasive, which is not the case with transdermal systems.
7
 Drug delivery 
through the skin allows for better control of dosage due to the impermeablility of the human 
skin
8
, and longer release periods of the drug.
6
 The transdermal systems are also noninvasive, can 
be self-administered, and are generally inexpensive
6
, making them highly favorable over the 
conventional drug delivery techniques.   
Transdermal drug delivery systems have become increasingly sophisticated over 
time.  The first transdermal system that was approved in the United States in 1979 was the 
motion sickness patch delivering scopolamine. The nicotine patch was approved for use ten years 
later.  Patch systems generally make up the first-generation transdermal delivery systems and are 
the most popular types of systems currently in clinical use.
6
 Other non-patch first-generation 
systems are in the form of liquid spray, gel or other types of topical formulations.
6
 The greatest 
limitation for first-generation systems, however, is the highly impermeable outermost layer of 
the skin called the stratum corneum.
6
 Drugs delivered through the first-generation approach must 
therefore be of low molecular weight, lipophilic and highly effective at low doses.
6
  
Second-generation transdermal delivery systems have also advanced clinical 
practice.  The goals of these second-generation systems include increasing the permeability of 
the stratum corneum, improving transport through the skin by adding a driving force, and 
preventing injury to deeper tissues.
6
 The greatest challenge has been finding the correct balance 
between increasing delivery rates, while preserving tissues from damage.
6
 Some of the main 
techniques used to achieve these goals have been the addition of chemical enhancers, 
iontophoresis and noncavitational ultrasound.
6
 Second-generation systems have mostly improved 
the delivery of small molecules.
6
 
Lastly, the third-generation transdermal systems represent the most sophisticated system 
designs.  These systems focus on targeting a stronger disruption of the stratum corneum while 
protecting deeper tissue layers.
6
 Techniques used have included novel chemical enhancers, 
electroporation, cavitational ultrasound, microneedles, thermal ablation, and 
microdermabrasion.
9
 These advanced methods are specifically relevant to macromolecule 
delivery; they are entirely excluded in first and second generation systems.
6
 Third-generation 
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systems however, are usually more aggressive and a balance between effectiveness and safety 
must be acknowledged. 
The advancements of transdermal systems have mainly worked to address the limitations 
of the skin.  The greatest limitation is that the skin has poor permeability due to the structure of 
the stratum corneum layer of the skin.
10
  Being able to effectively bypass this first layer is critical 
in expanding the applicability of transdermal drug delivery to larger molecules. While second 
and third generation systems have begun to address this, first-generation systems still prove to be 
the most clinically relevant systems. The complexity of second and third generation systems 
have introduced problems such as irritation and other safety concerns
10
 which must first be 
overcome before their approval for widespread use. 
For our project, we studied the advantages of using microcapsules for transdermal 
delivery. This method has attributes of both first and second generation systems. Drug-
containing microcapsules are typically applied topically, like first generation systems, but the 
microcapsules are targeted to go into hair follicles, which allow the drug to bypass the stratum 
corneum layer. Unlike typical second generation systems, there is no chemical modification of 
permeability involved, and the stratum corneum also remains perfectly intact. Therefore, the use 
of microcapsules provides a method that causes less damage to the skin and also offers a vehicle 
for molecules too large to diffuse directly through the stratum corneum.  
2.2 Design Objectives 
The primary objective of our project was to provide a COMSOL model of transdermal 
drug delivery using drug-containing microcapsules. COMSOL Multiphysics is an engineering 
design software that uses finite element analysis to simulate heat, mass, and fluid transfers in 
physical systems. Our model was used to validate the effectiveness of microcapsules in 
comparison to the case with drug in non-particle form.  Microcapsules would allow the transport 
the drug through a follicle and the release of the drug at deeper regions in the skin. Other 
objectives of our project were: 1) to determine the optimal initial concentrations and properties 
of drug-containing microcapsules needed to obtain a proper final drug dosage in the dermis skin 
layer; and 2) to verify the significance of follicles in transdermal drug delivery. 
In COMSOL, we modeled three separate types of diffusion.  The diffusion of 
microcapsules into a hair follicle was modeled using a patch-like applicator containing the initial 
amount of microcapsules. This applicator was placed above the follicle opening to mimic the 
diffusion of microcapsules located only in that specified area (disregarding microcapsules 
located in non-porous areas of the skin). Drug diffusion out of the microcapsules was modeled 
next, to follow the timed-release of the drug. A mass transfer governing equation was used, with 
diffusivity set to zero in each region of the skin, since this second diffusion was only used to 
track the change in concentration in the capsule over time. The last diffusion, the diffusion of 
drug into the skin layers, tracked the location of the drug after it left the microcapsule. These 
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three parts of our model satisfied the objective of obtaining a visual distribution of the drug in 
the epidermis and dermis skin layers. 
Our design was meant to model a "general" transdermally delivered drug with properties 
based off of several sources of literature. Parameters, such as drug diffusivity in each of the skin 
layers or through the microcapsule shell, and initial conditions, such as drug concentration in the 
capsule or amount of microcapsules applied to the skin surface, can be varied to determine the 
behavior of a specific drug. However, much experimental data is needed as a validation step to 
accurately simulate the delivery of a specific drug, especially since the use of microcapsules is 
still novel to most drugs. 
The stratum corneum, as well as the other skin layers, is mostly impermeable to 
microcapsules.
11
 For our design, we assumed that drug-containing microcapsules do not enter the 
skin layers and only penetrate the skin through the hair follicles or pores.  Also, microcapsules 
that enter the follicle do not all collect at the bottom.
11
 For some, the hair strand/particles/oily 
medium within the follicle disrupts their path. Therefore, the mechanism of microcapsule 
transport was assumed to be diffusion driven by a concentration difference of microcapsules on 
skin surface and at the bottom of the pore, with an equal distribution along the length of the 
follicle at steady state. To further simplify our model, the release of drug was assumed to be 
consistent out of all microcapsules (same shell thickness, same release reaction) and the initial 
drug concentration within each microcapsule was constant.  
2.3 Schematic 
In order to solve this problem using COMSOL, we made a 2D axisymmetrical model of a 
hair follicle in skin, with a drug source containing microcapsules directly above the follicle 
(Figure 1).  The hair follicle was modeled as a cylinder with radius 35µm.  The geometry was 
further simplified by considering the skin layers to be flat and even.  Within the drug source, 
there are 7.4*10
14 
microcapsules/m
3
, each with an initial drug concentration of 100,000g/m
3
 
within its core.  Each microcapsule has an inner radius of 300nm and an outer radius of 350nm 
(Figure 2).  The governing equations, boundary conditions, initial conditions, and material 
properties can be found in Appendix A. 
This design focused on the effect of a hair follicle used as a pathway for microcapsules to 
diffuse into the deeper skin layer. Therefore, the drug source box was designed directly above 
the hair follicle. Also, the size of the each region was confirmed with the literature sources to 
apply the realistic dimensions.  Microcapsules leave the drug source and enter the follicle, but 
they cannot diffuse into the epidermis or dermis.  Microcapsules release drug as they diffuse into 
the follicle, and the drug diffuses through the skin layers with different diffusivities, causing 
them to move more easily through the dermis than the epidermis. 
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 This design was successfully used to demonstrate the drug diffusion occurring through 
the hair follicle. However, it had some limitations of having only one hair follicle and only a 
partial drug source designed above the skin layer.  
 
Figure 1: Schematic of skin and hair follicle showing the source containing drug-loaded 
microcapsules above the follicle.  This model is 2D axisymmetrical. 
 
Figure 2: Dimensions of a typical microcapsule. 
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3. Results and Discussions 
3.1 Solution and Qualitative Description 
The COMSOL simulation of this project showed drug diffusion through the hair follicle, 
epidermis, and dermis, in a period of 4 hours. The surface plots of the concentration of both the 
microcapsules and drug in the skin layers showed that the microcapsules successfully aided in 
the distribution of the drug in the dermis layer.  
The capsules were thoroughly spread out in the hair follicle but did not penetrate the skin 
layers, since we set the diffusivity of capsules in the skin at zero to follow our model conditions 
(Figure 3). The microcapsule concentrations at the lower right corner of the follicle showed that 
the concentration reached steady state after approximately 4000 seconds (Figure 4). In other 
words, the microcapsules were evenly spread throughout the follicle after 67 minutes of diffusion. 
 
Figure 3: Surface plot of microcapsule concentration in the hair follicle region at time = 7,200 
seconds = 2 hours.  The capsules were thoroughly spread out in the hair follicle (red) but did not 
penetrate the skin layers (green). 
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Figure 4: Microcapsule concentration at the lower right corner of the follicle, over a 4 hour 
period.  The concentration reached steady state after approximately 4000 seconds. 
The surface plot of the drug in the skin layers showed that the drug diffused more easily 
in the dermis layer than in the epidermis layer, which is consistent with the fact that the drug has 
higher diffusivity in the dermis than in the epidermis (Figure 5). The two surface plots (Figure 5 
and 6) showed that more drug was concentrated around the hair follicle at two hours, and it 
diffused further out and away from the source of microcapsules and the hair follicle after four 
hours. 
 
Figure 5: Surface plot of drug concentration in the skin layers after 2 hours. This concentration 
plot (red: high conc.,blue: zero conc) shows the movement of drugs diffusing into the dermis 
layer more than the epidermis layer via the hair follicle pathway. After 2 hours, the drug is still 
highly concentrated right belove the drug source box. 
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Figure 6: Surface plot of drug concentration in the skin layers after 4 hours. The concentration 
plot (red: high conc.,blue: zero conc.) shows that more drug is diffusing into the dermis layer to 
reach the steady state in the domain. After 4 hours, a small region next to the hair follicle in the 
epidermis layer becomes highly concentrated with drug (dark red), because the drug 
continuously flows out of the hair follicle, but does not diffuse further into the epidermis layer 
because of the low diffusivity. 
In order to understand the process of drug diffusion out of the microcapsules and into the 
skin layers, we graphed the drug concentration at both the corner of hair follicle and the center of 
the dermis layer. Figure 7 shows that the concentration of drug near the hair follicle greatly 
increased within the first 2500 seconds and then started to decrease.  This trend showed that once 
the drug was released from the microcapsules, it first accumulated by the follicle and then 
diffused into the skin layer. In both locations, the drug concentration slowly reached the steady 
state concentrations. 
The concentration of the drug at the bottom of the follicle increased as the microcapsules 
moved down the pore and as more drug diffused out from the microcapsules. However, after a 
certain period of time, the concentration of the drug decreased, as it diffused into the dermis 
layer. The concentration of drug at the center of dermis region increased as more drug diffused 
out from the microcapsules and away from the follicle. Figure 7 shows that the concentration 
slowly increased at a point within the dermis layer, and will later reach a slight plateau. However, 
the amount of drug will eventually decrease as the drug diffuses deeper into the dermis skin layer 
(away from the follicle) or when the drug gets taken up into the bloodstream.  
To examine the changes in the concentration of drug in the capsule, we plotted the 
concentration over time (Figure 8). The initial concentration of drug at the microcapsule core 
was 100 mg/ml. The graph shows that the drug concentration in the capsules fell below 
25mg/mL after about 4,000 seconds.  Therefore, approximately 75% of the drug in the capsule 
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diffused out after 67 minutes, the time at which it took diffusion of the microcapsules to reach 
steady state. 
 
Figure 7: Drug concentration at the lower corner of hair follicle and at the center of 
dermis layer over a 4 hour period. The blue line shows how the drug accumulates near the hair 
follicle as it is released from the microcapsules, and the concentration decreases as it diffuses 
into the skin layer. The red line shows how the drug concentration in the center of dermis layer 
slowly reaches the steady state over time. 
 
Figure 8: Drug concentration in the microcapsule analyzed over a 4 hour period. This graph 
shows that about 70% of the drug diffuses out of the microcapsules after one hour. 
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3.2 Validation of the Design 
In order to validate the benefit that microcapsules provide for transdermal drug delivery 
in porous skin areas, we compared our original design with the microcapsule source placed 
directly above the hair follicle to a design where the microcapsule source was placed above the 
epidermis.  A point in the dermis layer below the follicle was chosen to compare the 
concentration change in the skin. As shown in Figure 9 and Figure 10, when the microcapsules 
were placed above the hair follicle, the drug diffused significantly more into the dermis layer 
after 4 hours than when the microcapsules were placed above the epidermis. The drug barely 
diffused into the epidermis layer when the capsules were placed above the skin surface.  
 
        Figure 11 depicts the concentration profile over time at a chosen point in the dermis skin 
layer. It shows a significantly lower drug concentration when the capsules are placed above the 
skin surface rather than directly above the follicle opening.  The drug concentration range varied 
from 0.0015ug/mL to 0.0006ug/mL for the original design, whereas the concentration barely 
reached 0.0001ug/mL for the new design.  This validates that the use of microcapsules for 
transdermal drug delivery in porous skin areas helps to achieve a higher concentration of drug in 
the dermis layer, along with a quicker diffusion of drug into deeper skin layers. 
 
Figure 9: Surface plot of drug concentration in the skin layers analyzed over a 4 hour period, 
when the capsules are diffusing into the hair follicle. (left) 
Figure 10: Surface plot of drug concentration in the skin layers analyzed over a 4 hour period, 
when the capsules are placed on the non-porous skin surface. (right) 
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Figure 11: Drug concentration at a point below the follicle analyzed over 4 hour period for (a) 
when the capsules are diffusing into the follicle (b) when the microcapsules are placed on the 
non-porous skin surface. 
3.3 Accuracy Check  
  An accuracy check of our design was conducted by comparing our results with results 
from related literature. In a pharmaceutical research article studying the follicular penetration of 
the drug adapalene from microcapsules,
1
 it was found that follicular penetration was related to 
the length of application time, which supports the increasing follicular concentration of 
microcapsules as a function of time in our model. As mentioned before, the capsules reached 
steady state and were evenly distributed in the follicle after 4000 seconds, which is about 67 
minutes (Figure 4).  
 In the same study, it was also shown that approximately 70% of adapalene diffused out 
of the microspheres in two hours.  In our model, 70% of the drug diffused out in about one hour 
(Figure 8). Although there is a difference of an hour, this time value is dependent on the drug 
diffusivity out of the microcapsule shell. Our model had a faster release rate, which would be 
appropriate for a drug that does not need to be released at high dosage at deeper skin layers. Our 
drug was released from the microcapsule quicker and at shallower skin layers as compared to the 
adapalene study. 
 
        For our model, we began with 100mg/mL as the initial concentration of drug in the 
microcapsules. The drug in the skin layer reached steady-state concentration at 0.0005 ug/mL 
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after approximately 4 hours of diffusion (Figure 7). This range is lower than the recommended 
amount of epinephrine in skin, which is 1 ug/mL.
2
 Once again, the effective concentration of the 
drug in the skin would vary with different drugs and different initial conditions. Our model 
appears to be most appropriate for a drug that requires a fast release rate but works in low 
dosages.  
Considering the limitations of our model, this measure of final concentration could be 
made more accurate by adding realistic complexities of the skin to our simplified design. Also, 
the skin contains many hair follicles and pores that would allow drug to efficiently diffuse into 
deeper skin layers. In our model, we only looked at microcapsules entering through a single hair 
follicle. Considering that the drug concentration near the end of hair follicle reached a peak 
concentration of  0.0033ug/mL and then slowly decreased to 0.0005ug/mL as more drug diffused 
into skin layers, the steady state drug concentration would likely be higher in a region with 
multiple hair follicles.   
        For simplification purposes, we applied the microcapsules solely on top of the hair 
follicle.  In a more realistic situation however, the drug will likely be applied throughout the skin 
surface rather than just over the hair follicles.  A slight modification to our original design was 
done to test how having a thin layer of drug over the entire skin surface (in addition to direct 
application above the follicle opening) would affect the drug concentration in the deeper skin 
layers. This design resulted in an average concentration of 0.015ug/mL, a larger concentration 
value that more closely resembles the recommended concentration of epinephrine in skin (Figure 
12, Figure 13).  It is important to note however, that this model assumes that the drug in question 
is permeable to the stratum corneum.  There would not be a difference in the concentration found 
in the skin if the drug was completely impermeable through the stratum corneum.  In this case, 
the use of microcapsules as vehicles to bypass the stratum corneum becomes all the more 
important for effective drug delivery.   
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Figure 12: Surface plot of drug concentration with the thin drug layer over the skin surface, 
analyzed over a 4 hour period. A slight modification of having a thin layer of drug in the design 
resulted in an average concentration of 0.015ug/mL, significantly larger than that of the original 
design, which was 0.0005ug/mL. 
 
Figure 13: Drug concentration for the two scenarios: (1) when microcapsules are only placed 
directly over the hair follicle (as a small drop) and, (2) when microcapsules are placed over the 
entire skin surface (as a thin layer). 
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3.4 Sensitivity Analysis 
Since our design objective was to model the behavior of a "general" transdermally 
delivered drug, the parameters used for our COMSOL simulation were estimates of values found 
in related literature. Sensitivity analyses were done on drug and microcapsule properties to 
determine how the final result, calculated as the total amount of drug delivered to the different 
skin layers after 4 hours, would change in response to varying parameters and initial 
concentrations. These sensitivity analyses are essential in identifying the inputs that contribute 
the most variability and potential error, while also serving as a reference for future researchers 
who wish to implement our design experimentally with a chosen drug of interest. 
For our simulation, using the input parameters shown in Appendix A, we obtained 
9.74*10
-13
 grams of drug in the dermis skin layer, and 1.06* 10
-12
 grams of drug in the epidermis 
and dermis skin layers combined, after 4 hours of microcapsule application. These values were 
obtained using a subdomain integration for drug concentration at 4 hours (14400 seconds) for the 
specified skin layers, and are shown in Figure 14 as the two gray dotted lines. Our values chosen 
for the diffusivity of drug through the follicle, 2.5e-10 m
2
/s, and the diffusivity of microcapsules 
through the follicle, 2.2e-10 m
2
/s, were good estimates. Although these parameters were not 
found in literature and were approximations, the sensitivity analyses show that the total amount 
of drug in the dermis starts to plateau at those values. The red and blue plots in Figure 14 show 
that there is no significant change in the total amount of drug with diffusivity values above 
1.0*10
-10
 m
2
/s, but the total amount exponentially decreases below 1.0*10
-10
 m
2
/s. 
A second sensitivity analysis showed the total amount of drug in the dermis after 4 hours 
is very sensitive to drug diffusivity through the epidermis. When the drug diffusivity through the 
epidermis was increased, the drug concentration in the dermis layer decreased, most likely due to 
an accumulation of drug in the epidermis layer and less distribution to the lower dermis layer. As 
shown in Figure 14 as the green plot, our value of 3.30*10
-13
 m
2
/s is found in a region where the 
drug amount constantly changes with changes of this diffusivity parameter.  
Similarly, our value of 1.20*10
-11
 m
2
/s for drug diffusivity through the dermis skin layer 
also lies in a varying region; an increase in drug diffusivity through the dermis layer produced a 
decreasing drug amount in the epidermis and dermis layers as shown in Figure 14 as the purple 
plot. However, this trend is not as significant as the trend for drug through epidermis. A drug 
with better diffusivity values through the dermis are more easily distributed to the skin. 
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Figure 14: Sensitivity analysis for four diffusivity parameters: (1) drug diffusivity through 
follicle, (2) microcapsule diffusivity through follicle, (3) drug diffusivity through epidermis, (4) 
drug diffusivity through dermis. For (1)-(3), the total amount of drug in the dermis layer was 
used for analysis. The green line (3) shows the reduction in the total amount of drug in the 
dermis layer, since diffusivity of drug through the epidermis layer is increasing, causing more 
drug to diffuse into the epidermis and less into the dermis. For (4), the total amount of drug in 
both the epidermis and dermis layers was used for analysis. The two dotted gray horizontal lines 
indicate the values we obtained for total amount of drug in dermis layer (lower gray line) and 
total amount of drug in epidermis and dermis layers (upper gray line). 
The sensitivity analysis conducted for initial concentration of drug within a microcapsule 
shows that the amount of drug in the dermis layer after 4 hours increases linearly with an 
increase in this initial condition (Figure 15). The results of this analysis can be useful for 
researchers hoping to obtain a specific dosage of drug in the dermis layer after a specific 
application time. 
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Figure 15: Sensitivity analysis for the initial concentration of drug within the microcapsule, 
using total amount of drug in the dermis layer for analysis. The value we used in our design is in 
orange. 
In the sensitivity analysis done for drug diffusivity out of the microcapsule, Figure 16 
shows that our value of 1.50*10
-18
 m
2
/s (obtained from literature
11
) is the optimal value. This 
diffusivity value incorporates properties of the microcapsule shell and its interaction with the 
contained drug and is responsible for the "timed-release" of the drug. With this optimal value, 
microcapsules were best able to keep the drug contained until they bypassed the epidermis skin 
layer, thereby releasing most of the drug in deeper regions of the skin and obtaining the greatest 
amount of drug in the dermis layer at 4 hours after microcapsule application. 
 
Figure 16: Sensitivity analysis for drug diffusivity through the microcapsule shell, using the total 
amount of drug in the dermis layer for analysis. The value we used in our design is in red. 
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4. Conclusion 
 
4.1 Goals 
Our goal in this project was to test the effectiveness of using microcapsules for 
transdermal drug delivery.  One of the major challenges in the current state of research that we 
addressed was the problem of getting a drug past the stratum corneum layer of the skin.  We also 
aimed to determine the relationship of initial drug concentration and skin layer properties with 
the final steady-state drug concentration in the dermis. In summary, this project aimed to verify 
the significant role of hair follicles in drug delivery. 
In our model, we studied the diffusion of drug-loaded microcapsules in a single hair 
follicle.  To verify that drug diffusion into the skin is, in fact, more efficient via the follicular 
pathway utilized by the microcapsules, we ran a problem in COMSOL with the microcapsule 
source placed on the skin surface (Figure 10).  From this experiment, we were able to confirm 
that drugs are able to diffuse faster into the skin with the use of microcapsules in hair 
follicles.  We can therefore conclude that hair follicles, in combination with microcapsules used 
as vehicles, play a significant role in efficient drug delivery. This is, therefore, an effective 
method for bypassing the highly impermeable stratum corneum layer. 
We also examined the relationship between the initial drug concentration in the 
microcapsules, and the skin layer diffusivity properties, on the final drug dosage achieved in the 
dermis, through a series of sensitivity analyses.  Changes in the diffusivity properties of the skin 
layers greatly affected the final drug concentration in the skin.  We found that increasing the 
diffusivity values of the dermis and follicle led to higher final concentrations, which was 
expected.  We learned, however, that this was not the case for increasing the diffusivity of the 
epidermis, where we found a decrease in the final drug concentration.  When the initial 
concentration of drug in the microcapsule was varied, we found that the final concentration in the 
skin was directly correlated to the initial concentration in the microcapsule.  These relationships 
would be very useful for optimizing drug concentration values for a specific drug.  
 
 4.2 Improving the Design 
Our model provided a simple but comprehensive understanding of drug diffusion through 
microcapsules and hair follicles.  In order to obtain a more accurate solution however, the many 
simplifications in our design could be adjusted and the realistic complexities of actual skin could 
also be added.  While we only studied diffusion through one hair follicle, studying several hair 
follicles in a representative region of the skin could lead to changes in the final drug dosage 
achieved in the skin.  We also modeled the hair follicle, epidermal layer, the dermal layer and the 
stratum corneum (as a boundary condition), as straight blocks.  Real skin contains many sub-
layers within the epidermis and dermis and has more curvatures in structure.  Different sub-
layers are likely to vary in diffusivity.  Skin also contains other components such as pores, sweat 
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ducts, glands, nerves, blood vessels, muscles, and fat tissue which could all affect the diffusion 
of drug throughout the skin.   
Lastly, our model assumed that the size of drug molecule is small enough to diffuse into 
the epidermis layer, but big enough to have some difficulties when diffusing all the way to the 
dermis layer. This is important to note when comparing topical drug application and 
microcapsule application because some drug molecules are physically too large to pass through 
the skin layers at all. Although we specified the boundary condition representing the stratum 
corneum as zero flux, we still had some diffusion of drug occur which would only be relevant to 
cases where the drug particles were somewhat permeable to the stratum corneum.  If we could 
specify a drug particle size, our solution could reflect situations that would occur depending on 
the drug size.   
Despite the many simplifications of our model, we were still able to simulate and draw 
important conclusions of the transport of drug through the skin in this microcapsule transdermal 
system.  
4.3 Difficulties 
During the course of our project, we faced several difficulties in achieving our 
goals.  The first challenge was in capturing the complex diffusion processes occurring in real 
skin in our design.  Our problem was unique because it involved two separate diffusion 
processes, the first being the diffusion of microcapsules into the follicles and the second being 
the simultaneous diffusion of drug out of the microcapsules.  With the help of our professor and 
teaching assistants, we were able to derive suitable governing equations to model these two 
diffusion processes.  In COMSOL, we actually used three diffusion equations, where the last 
equation kept track of the drug concentration changes inside the microcapsules.   
Another difficulty we faced was finding realistic property values.  Since this was a 
problem we anticipated, we researched many different diffusivity values reflecting behaviors of 
many different drugs.  Due to the varying amount of information available for different drugs, 
we decided not to choose a specific drug and went forward with values that appeared most 
common and reasonable for a general drug model.  This however, led to other minor problems 
which were discovered during our accuracy check and validation.  We found that our design 
conditions led to a slightly high release rate of the drug and a low final drug concentration in the 
skin.  This indicated that our model would best reflect the behavior of a potent drug requiring a 
fast release rate and a low dosage in skin. 
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4.4 Realistic Constraints and Design Recommendations 
Aside from the limitations in our model resulting from simplifications in the design, we 
must also consider other realistic constraints such as manufacturability, ethical, and health and 
safety issues.  In terms of manufacturability, there are currently many transdermal systems in the 
form of patches available to the public.
6
 Given the efficiency of drug delivery that transdermal 
systems offer, they would be more cost effective to manufacture, since drug would not be wasted 
as much as in other delivery methods.  The ease of application of the drug would also contribute 
to the feasibility of producing transdermal systems, since medical professionals would not be 
needed. Ethical concerns in transdermal drug delivery systems could arise if animal testing is 
used. Established ethical practices will need to be carefully applied to this system in order to 
ensure that codes are not violated.  
Lastly, health and safety concerns are the most important constraints in transdermal drug 
delivery research.  Aside from tightly controlling the drug release rates, the best way to monitor 
safe administration of the drug would be education of proper use.  For example, if certain 
external or internal conditions may alter drug release rates, it is important for manufacturers to 
address these warnings.  In this way, responsibilities must be balanced between the manufacturer 
and user.  Our model did not have significant realistic constraints, which additionally makes 
transdermal drug delivery systems a favorable method for drug delivery. 
This design is recommended for those who are interested in studying the microcapsule 
drug delivery system for the practical use. Since this project was designed to study the delivery 
of any “general” drug, when the design is used for one specific drug, the new sets of parameters 
(especially diffusivities) must be accurately chosen for the drug of interest to obtain satisfying 
results for analysis. This model simulation would be very useful for obtaining a target final drug 
dosage in skin layers. However, one must be aware that there are limitations to our design and 
this could be improved by adding necessary variations into the design. The size and location of 
drug source box or the number of hair follicles in the design can be changed to apply the model 
to the real situations and obtain accurate results. The number of follicles can be considered based 
on the application location of the drug. It is also recommended to avoid the use of this model, 
and any transdermal drug delivery system, for open wounds or mucosal linings. 
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5. Appendix A: Mathematical statement of the problem 
Governing Equations 
Diffusion of microcapsules - mass species equation with transient and diffusion terms: 
 
 
Diffusion of drugs – mass species equation with transient and diffusion terms, with an added 
“generation” term that actually represents drug leaving the microcapsule core: 
 
Equation for drug concentration in the core – mass species equation with transient term, with an 
added “generation” term that actually represents drug in the microcapsule core. 
 
Variables: 
Cb= number of microcapsules / cm
3
 
Db= diffusivity of microcapsules 
Cd= concentration of drug 
Dd= diffusivity of drug in skin layers 
CNR= concentration of drug in the core of microcapsule 
rD= radius of microcapsule outside 
ri= radius of microcapsule inside 
 
Boundary Conditions 
All interior boundaries were considered continuities for both the diffusion of microcapsules and 
the diffusion of drug.  However, material property differences account for changes in diffusivity 
from region to region.  All exterior boundaries were considered to have the condition flux = 0, as 
they were either far from the source or interfacing with air. 
Initial Conditions 
The initial concentration of microcapsules (Cb,0) in the drug source was calculated based on the 
outer radius of the microcapsule, and assuming close packing of the microcapsules, as 7.4*10
14 
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microcapsules/m
3
.  The initial concentration of the drug in the core of the microcapsules (CNR,0) 
was determined based on common drug concentrations.  Many topical drugs claim to have a 
0.01% mass/volume drug formulation.  If the microcapsule formulation were to be equivalent, 
the same mass of drug would be present, but it all would be contained in the microcapsule cores, 
which is a much smaller volume.  A basic mass balance was done, to find an initial concentration 
in the core, of 100,000g/m
3
. 
Input parameters 
The following input parameters are listed with the reference that was used to decide on the 
parameter.  The full references can be found at the end of this document.  
Table 1: Diffusivity, Microcapsule Sizes and Its Sources 
Constant Value Reference 
Diffusivity, drug in microcapsule shell 1.5 * 10
-18
m
2
/s Yow 2009 
Diffusivity, drug in epidermis 3.3* 10
-13
m
2
/s Dalby 2001 
Diffusivity, drug in dermis 1.2* 10
-11
m
2
/s Filer 1994 
Diffusivity, drug in hair follicle 2.5*10
-10
m
2
/s Frum 2007 
Diffusivity, microcapsules in hair 
follicle 
2.2*10
-10
m
2
/s Sonavane 2008 
Diffusivity, microcapsules in skin 0 m
2
/s Assumption 
Microcapsule outer radius 350 nm Yow 2009 
Microcapsule innter radius 300 nm Yow 2009 
 
 
 
 
 
 
 
 
 
 
 
Group 9 Page 23 
 
6. Appendix B: Solution Strategy 
Solver 
We solved our problem with COMSOL using the direct finite element method because our 
schematic was simple enough to not require the use of an iterative method.  
Time Stepping 
We used a constant time step of 10 seconds, for a period of four hours, or 14,400 seconds.  This 
was a sufficient amount of time for most of the drug to leave the microcapsules and to diffuse 
throughout the dermis. 
Tolerance 
We used COMSOL’s default values of 0.01 for relative tolerance and 0.0010 for the absolute 
tolerance.  
Mesh / Mesh Convergence 
For mesh convergence, we used mapped mesh for our computational domain. After reaching 800 
mesh elements, the average concentration of drug in the dermis layer converges to 2.92*10
-4 
g/m
3
.
 
For mesh convergence, we used mapped mesh for our computational domain. The graph 
shows that after reaching 800 mesh elements the average concentration of drugs in the dermis 
layer converges to 2.92*10
-4
g/m
3
(Figure 17 and Table 2). We decided to use 812 mesh elements 
of mapped mesh for our computation. 
 
Table 2: The number of elements and average concentration of drug in dermis after 4 hours 
Number of 
elements 
Total amount of drug 
in dermis [grams] 
Average concentration of drug 
in dermis [grams/m3] 
72 1.53E-12 4.55E-04 
255 1.11E-12 3.30E-04 
420 1.03E-12 3.05E-04 
812 9.80E-13 2.92E-04 
2650 9.81E-13 2.92E-04 
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Figure 17: The mesh convergence analysis on the concentration of drug in the dermis region vs. 
number of mesh elements. 
 
Figure 18: The final mapped mesh of the computational domain with 812 mesh elements 
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